Search Results
Nov 03, 2025, 01:26 ET Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease
has initiated a Phase IIa clinical trial to evaluate the safety and biomarker-based efficacy of AT-001 in individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD). The multicentre, randomized, double-blind, placebo-controlled, dose-escalation study will assess the
More news about: Arctic Therapeutics
Oct 30, 2025, 06:33 ET Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 9 countries. Following the initial phase
More news about: BioArctic
Oct 30, 2025, 06:30 ET Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 9 countries. Following the initial phase
More news about: BioArctic
Oct 27, 2025, 07:45 ET New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
specificity to meet acceptable performance of confirmatory blood biomarker tests in an intended-use population of 215 patients with mild cognitive impairment (MCI) or Alzheimer's disease in which 46% were amyloid PET-positive. Both the
More news about: Quest Diagnostics
Oct 26, 2025, 22:58 ET Health Canada Grants Authorization for Leqembi® (lecanemab)
Lecanemab is approved in the U.S., Japan, EU, China, Great Britain, and several other markets for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. Lecanemab's approvals in these countries, as well as the EC's market authorization, were primarily
More news about: BioArctic
Oct 26, 2025, 22:56 ET Health Canada Grants Authorization for Leqembi® (lecanemab)
Lecanemab is approved in the U.S., Japan, EU, China, Great Britain, and several other markets for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. Lecanemab's approvals in these countries, as well as the EC's market authorization, were primarily
More news about: BioArctic
Oct 23, 2025, 12:00 ET Czech Breakthrough in Medicine: H₂ Global Group Receives Regulatory Approval for Hydrogen Clinical Study -- New Era in Alzheimer's Therapy Begins
Institute for Drug Control (SÚKL) to initiate a clinical study focused on molecular hydrogen inhalation therapy for patients with mild cognitive impairment (MCI), an early stage of Alzheimer's disease.
More news about: H2 Global Group
Oct 15, 2025, 07:03 ET Delta Development Team Launches BloodCOMM Premium: Empowering EMS Leadership to Drive Accountability and Save Lives
planning. Embed Compliance: Policy adherence and inspection checks built directly into workflows. Ensure MCI Readiness: Per-bag tracking to reduce waste and optimize mass casualty responses. Use Data to Lead: Analytics that reveal
More news about: Delta Development Team
Oct 14, 2025, 03:30 ET First patient treated with Leqembi® (lecanemab) in the Nordics
Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL), which measures information provided by people caring for patients with AD, noted 33% less decline compared to placebo at 18 months. The adjusted mean change from baseline at 18 months in the ADCS MCI-ADL score was −3.873 in the lecanemab group and
More news about: BioArctic
Oct 14, 2025, 01:18 ET Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 10 countries. Leqembi Iqlik™ is approved
More news about: BioArctic
Oct 14, 2025, 01:14 ET Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 10 countries. Leqembi Iqlik™ is approved
More news about: BioArctic
Oct 13, 2025, 19:30 ET LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab
More news about: Eisai Inc.
Oct 07, 2025, 07:00 ET Lilly and Leading Alzheimer's Disease Experts Call for Urgent Action to Close Diagnostic Gaps at Alzheimer Europe Conference
Disease Specific Programme™ (Adelphi DSP) - a multinational and cross-sectional survey of clinicians treating patients with mild cognitive impairment (MCI) and AD patients in France, Germany, Italy, Spain, the United Kingdom, Japan, and the United States - experts warn that AD and dementia remain critically
More news about: ELI LILLY & COMPANY
Oct 07, 2025, 07:00 ET Lilly and Leading Alzheimer's Disease Experts Call for Urgent Action to Close Diagnostic Gaps at Alzheimer Europe Conference
Disease Specific Programme™ (Adelphi DSP) - a multinational and cross-sectional survey of clinicians treating patients with mild cognitive impairment (MCI) and AD patients in France, Germany, Italy, Spain, the United Kingdom, Japan, and the United States - experts warn that AD and dementia remain critically
More news about: ELI LILLY & COMPANY
Oct 07, 2025, 07:00 ET Lilly und führende Alzheimer-Experten fordern auf der Alzheimer Europe Konferenz dringende Maßnahmen zur Schließung von Diagnoselücken
Specific Programme™ (Adelphi DSP) - einer multinationalen Querschnittsbefragung von Klinikern, die Patienten mit leichter kognitiver Beeinträchtigung (MCI) und Alzheimer-Patienten in Frankreich, Deutschland, Italien, Spanien, dem Vereinigten Königreich, Japan und den Vereinigten Staaten behandeln - warnen
More news about: ELI LILLY & COMPANY
Oct 07, 2025, 07:00 ET Lilly et d'éminents experts de la maladie d'Alzheimer appellent à une action urgente pour combler les lacunes en matière de diagnostic lors de la conférence Alzheimer Europe
Programme™ (Adelphi DSP) - une enquête multinationale et transversale auprès de cliniciens traitant des patients atteints de troubles cognitifs légers (MCI) et des patients atteints de la MA en France, en Allemagne, en Italie, en Espagne, au Royaume-Uni, au Japon et aux États-Unis - les experts avertissent
More news about: ELI LILLY & COMPANY
Oct 06, 2025, 18:05 ET Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of Leqembi intravenous (IV) treatment at 10 mg/kg every two
More news about: BioArctic
Oct 06, 2025, 18:02 ET Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of Leqembi intravenous (IV) treatment at 10 mg/kg every two
More news about: BioArctic
Oct 06, 2025, 16:30 ET Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab
More news about: Eisai Inc.
Oct 04, 2025, 19:08 ET Family Seeks Public's Help in Search for Missing Teen Michael Kocabay
#25180288. About Moses Castillo Investigations, LLC Led by retired LAPD Detective Supervisor Moses Castillo, MCI specializes in high-profile and sensitive investigations with a trauma-informed approach. Castillo is a nationally recognized advocate for victims and
More news about: Moses Castillo Investigations, LLC
Oct 02, 2025, 15:08 ET Mazda informa los resultados de ventas de septiembre
Las mejores ventas de septiembre del CX-50 con 8,876 vehículos vendidos. Mazda Canada, Inc., (MCI) informó ventas en septiembre de 7,996 vehículos, un aumento del 18.5 % en comparación con el año pasado. Las ventas en lo que va del año totalizaron
More news about: Mazda North American Operations
Oct 01, 2025, 10:30 ET Mazda Reports September Sales Results
1995. Best September sales of CX-50 with 8,876 vehicles sold. Mazda Canada, Inc., (MCI) reported September sales of 7,996 vehicles, an increase of 18.5 percent compared to last year. Year-to-date sales totaled 64,017 vehicles sold; an increase
More news about: Mazda North American Operations
Oct 01, 2025, 10:00 ET Linus Health Showcases Role of Digital Tools and Biomarkers in Early Brain Health Detection at AAFP's FMX 2025
helped physicians detect mild cognitive impairment (MCI) earlier, streamline referrals, and initiate proactive brain health management for at-risk patients.
More news about: Linus Health
Sep 29, 2025, 02:38 ET Leqembi® approved for IV maintenance treatment in China
In January 2024, lecanemab was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks
More news about: BioArctic
Sep 29, 2025, 02:34 ET Leqembi® approved for IV maintenance treatment in China
In January 2024, lecanemab was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks
More news about: BioArctic